Lysando and AiCuris have signed a long-term cooperation for the development and optimization of Artilysin(R)-based drug candidates for various anti-bacterial indications.   Both companies will collaborate in the identification and optimization of new Artilysin(R)-based drug candidates for the treatment of bacterial infections, including e.g. hospital-acquired pneumonia, sepsis and cystic fibrosis. AiCuris will receive exclusive access to Lysando’s Artilysin(R) technology to generate Arti...